School of Medicine, Trinity College Dublin, College Green, Dublin 2, Ireland.
Ir J Med Sci. 2011 Jun;180(2):337-41. doi: 10.1007/s11845-011-0685-5. Epub 2011 Feb 4.
The prevalence of multiple sclerosis (MS) in Ireland is well over the European and global averages and the costs associated with managing this disease are placing a heavy economic burden on the Irish healthcare system. This paper investigates how current therapies used to treat MS are impacting on the total cost of MS as well as the potential impact of oral therapies in the MS marketplace.
Sales and expenditure data on MS disease-modifying drugs were reviewed as were market reports on forthcoming therapies in the MS pipeline. Clinical trial results for both current and prospective compounds were also reviewed to analyse how safety and efficacy data are influencing drug availability and expenditure.
The high cost of disease-modifying drugs is substantially increasing the total cost of MS in Ireland. Newer therapies are likely to contribute to this trend. Safety concerns continue to be a barrier to advancement of the most promising compounds in the MS pipeline.
Structures and/or treatment algorithms may be needed to help manage the growing cost of treating MS in Ireland to ensure all patients have access to safe, efficacious treatments.
爱尔兰多发性硬化症（MS）的患病率远远高于欧洲和全球平均水平，管理这种疾病的相关费用给爱尔兰医疗保健系统带来了沉重的经济负担。本文研究了目前用于治疗 MS 的疗法如何影响 MS 的总成本，以及口服疗法在 MS 市场中的潜在影响。
审查了多发性硬化症疾病修正药物的销售和支出数据，以及多发性硬化症市场报告中即将推出的疗法。还审查了当前和潜在化合物的临床试验结果，以分析安全性和疗效数据如何影响药物的供应和支出。
疾病修正药物的高昂成本大大增加了爱尔兰多发性硬化症的总成本。较新的疗法可能会助长这一趋势。安全性问题仍然是多发性硬化症市场中最有前途的化合物发展的障碍。
可能需要结构和/或治疗算法来帮助管理爱尔兰治疗多发性硬化症的成本增长，以确保所有患者都能获得安全有效的治疗。
